Keyphrases
Cost-effectiveness
86%
Quality-adjusted Life Years
56%
Cost-effectiveness Analysis
45%
Spain
44%
Acute Migraine
43%
Almotriptan
42%
Spasticity
31%
Triptans
30%
Multiple Sclerosis Spasticity
28%
Sativex
28%
Activity-based Costing
28%
Transcatheter Aortic Valve Replacement
28%
Oral Triptans
28%
Glioma Surgery
28%
5-Aminolevulinic Acid (5-ALA)
28%
Malignant Glioma
28%
Incremental Cost-effectiveness Ratio
27%
Incremental Cost
24%
Multiple Sclerosis
24%
Gross Total Resection
21%
Economic Evaluation
18%
Life-years Gained
18%
Severe Aortic Stenosis
18%
Adverse Events
16%
Spanish Hospitals
16%
Migraine Attack
16%
RFSH
14%
Pen Device
14%
Surgical Replacement
14%
Historical Cost
14%
Fair Value Accounting
14%
Acute Migraine Treatment
14%
Prostamide
14%
Intrathecal Baclofen Therapy
14%
Non-focal
14%
Activity Design
14%
Business Accelerator
14%
Financial Reports
14%
Financial Accounting Information
14%
Accounting Firms
14%
Cost-effectiveness Model
14%
Firm Performance
14%
Specialty Care
14%
Glaucoma
14%
Bone Metastasis
14%
Cost-utility
14%
Early Treatment
14%
Induced Fluorescence
14%
Cost Comparison
14%
Frequent Use
14%
Medicine and Dentistry
Health Care Cost
100%
Cost-Effectiveness Analysis
79%
Quality Adjusted Life Year
42%
Spasticity
28%
Glioblastoma
28%
Aminolevulinic Acid
28%
Percutaneous Aortic Valve Replacement
28%
Surgery
21%
Aortic Stenosis
16%
Nabiximols
14%
Multiple Sclerosis
14%
Combination Therapy
14%
Migraine
14%
Pamidronic Acid
14%
Baclofen
14%
Transcatheter Aortic Valve Replacement
14%
Zoledronic Acid
14%
Prostate Hypertrophy
14%
Bone Metastasis
14%
Retrospective Study
14%
Early Intervention
14%
Cost-Minimization Analysis
14%
Apoplexy
14%
Progression Free Survival
10%
Health System
7%
Public Health
7%
Drug Therapy
5%
Observational Study
5%
Sabal Extract
5%
Almotriptan
5%
Tamsulosin
5%